A nationwide public health–focused clinical trial that compared the effectiveness of “first generation” (introduced in the 1950s) and “second generation” (available since the 1990s) antipsychotic medications. Phase i of catie analyzed the economic implications of antipsychotic treatment and concluded that the older conventional antipsychotic perphenazine was less expensive and no less effective than the newer atypical antipsychotics olanzapine, quetiapine, risperidone, and ziprasidone during initial treatment, suggesting that older antipsychotics still have a role in treating schizophrenia. The study was funded by the national institute of mental health (NIMH).
The development of new drugs consists of 4 phases: 1. preclinical studies, 2. clinical studies phase I, 3. clinical studies phase II and 4. clinical studies phase III.